STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Clinical trials for STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
Disease control OngoingThis phase I trial is testing whether a combination of three treatments — an experimental drug called elimusertib, precise radiation therapy, and the immunotherapy pembrolizumab — can shrink or stabilize recurrent head and neck cancer that cannot be removed by surgery. The study …
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Weekly chemo may be gentler for head and neck cancer patients
Disease control TerminatedThis study compares two ways of giving the chemotherapy drug cisplatin alongside radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose weekly. The goal is to see if the weekly schedule causes fewer side …
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New Drug-Radiation combo shows promise for Tough-to-Treat head and neck cancer
Disease control OngoingThis early-phase trial is testing whether adding the drug peposertib to standard radiation therapy is safe and effective for people with advanced head and neck cancer who cannot take the chemotherapy drug cisplatin. The study involves 21 participants and aims to find the best dos…
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC